August 4, 2025

Dexmedetomidine improves early quality of recovery but not reduce risk of chronic postsurgical pain after intraoperative neuromonitoring thyroidectomy, a randomized trail.

View Full Paper

Ask AI

Bookmark

MAIN FINDING: Dexmedetomidine improves quality of recovery on postoperative day 1 and day 3 compared to placebo.
KEY EVIDENCE: Global QoR40 scores significantly higher in dexmedetomidine group: POD1 scores 177.93 vs. 159.34, and POD3 scores 184.67 vs. 175.90 (P < 0.05).
APPROACH: Sixty patients undergoing neuromonitoring thyroidectomy were randomized into two groups, receiving either dexmedetomidine or saline.
SIGNIFICANCE: Although dexmedetomidine enhances immediate recovery, it does not decrease the incidence of chronic postsurgical pain.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial shows dexmedetomidine improves quality of recovery in thyroidectomy patients, suggesting benefits without reducing chronic postsurgical pain.

Cite This Study

Sun et al. (2025) studied this question.

synapsesocial.com/papers/689a0f86e6551bb0af8d09d1 https://doi.org/10.21203/rs.3.rs-6385340/v1

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows dexmedetomidine improves quality of recovery in thyroidectomy patients, suggesting benefits without reducing chronic postsurgical pain.

Dexmedetomidine improves early quality of recovery but not reduce risk of chronic postsurgical pain after intraoperative neuromonitoring thyroidectomy, a randomized trail.

Key Points

Discussion

Implication

Cite This Study

Dexmedetomidine improves early quality of recovery but not reduce risk of chronic postsurgical pain after intraoperative neuromonitoring thyroidectomy, a randomized trail.

Key Points

Discussion

Implication

Cite This Study